Weekly paclitaxel in the adjuvant treatment of breast cancer.
By J. Sparano, Molin Wang, S. Martino, V. Jones, E. Perez, T. Saphner, A. Wolff, G. Sledge, W. Wood, N. Davidson. New England Journal of Medicine, 2008
863 citations recorded by the source corpus.
Subfields: Cancer Research, Oncology, Pathology and Forensic Medicine
View Paper: https://www.semanticscholar.org/paper/972a8c65cc875ef46fe5ad66da949cb2fda63bea
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Oncology
In Pathology and Forensic Medicine
Citations in the corpus
- Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. (2014, methodology): “one of four taxane regimens after doxorubicin plus cyclophosphamide once every 3 weeks for four cycles: taxol 175 mg/m(2) once every 3 weeks for four cycles, taxol 80 mg/m(2) once per week for 12 weeks, docetaxel 100 mg/m(2) once every 3 weeks for four cycles, or docetaxel 35/m(2) once per week for ”
- Triple-negative breast cancer--current status and future directions. (2009, result): “This is in line with recent data regarding weekly paclitaxel after four cycles of AC indicating that the benefit of paclitaxel q1w (but not docetaxel) compared with paclitaxel q3w was pronounced in the TNBC and HR+/HER-2 subgroups [115].”
- Breast Cancer Treatment: A Review (2019, background): “Years indicated are the year of initial presentation/publication of the relevant evidence, though additional significant references are included as well (197635; 199034,36; 199834,37-39; 200340,41; 200642; 201743).”
- Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2013, background): “Their weekly application has been shown to be associated with lower risk of haematological toxic effects and shorter nadir periods [29, 30], warranting the consideration of this approach in pregnant cancer patients [IV, C].”
- Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015, neutral): “FE100C 6 3 [35] CE1,8F 6 4 [13, 56] A (or E)/CMF 4/4 (–8) 3/4 [14, 71] AP/CMF 4/4 3/4 [37] DC 4 3 [53] AC/P(H) qwk 4/4 3/3 [76, 84] AC/D(H) 4/4 3/3 [84]”